PATH Biotech

Executive Summary

PATH Biotech is a privately held US biotechnology company founded in 2016 and headquartered in Cambridge, MA. The company leverages a proprietary AI platform to discover novel drug targets and develop precision small-molecule therapeutics for neurodegenerative diseases, cancer, and autoimmune disorders. By translating computational insights into clinical candidates, PATH aims to address high unmet medical needs in areas where traditional drug discovery has been challenging. The company’s AI-driven approach enables faster identification of target-disease associations and optimization of drug candidates, potentially reducing development timelines and costs. PATH has not yet disclosed its total funding or valuation, and remains in a pre-clinical or early clinical stage based on available information.

Upcoming Catalysts (preview)

• TBDAnnouncement of lead candidate nomination for IND-enabling studies60% success
• TBDPresentation of preclinical efficacy data at a major scientific conference70% success
• TBDStrategic partnership or licensing deal for AI platform or drug candidate50% success